Research Research Programs Biotechnology, Imaging & Drug Development Systems, Pathways & Targets Cancer Control Clinical Research Stern Center for Cancer Clinical Trials and Research Disease-Oriented Teams Protocol Review and Monitoring Committee Research Resources Membership Guidelines Shared Resources Acknowledgement of Grant and Shared Resources Anti-Cancer Challenge Research Anti-Cancer Challenge Pilot Research Projects Anti-Cancer Challenge Past Awardees Team Funds Centers & Institutes Space Management and Requests Funding Opportunities A1 Bridge Funding Cancer Health Disparity Research and Interventional Studies Disease-Oriented Teams Home Research Clinical Research Disease-Oriented Teams Disease-Oriented Teams are multidisciplinary groups of basic, translational, clinical, and population health investigators who collaborate on a specific cancer area in order to further the translation of CFCCC discoveries through the pipeline towards interventional clinical trials. As the first component of the CFCCC’s two-step clinical research review process, the focus of the DOTs is to ensure rigorous internal scientific review of protocols, curate the clinical trial portfolio, and drive innovation. What Does a DOT Do? Through their collective expertise, DOTs steward the Cancer Center's clinical research efforts, managing the clinical trials portfolio around the following principles: scientific merit, soundness of trial design, accrual potential, and likelihood for correlative translational science. Facilitate the translation of scientific discoveries to address specific types of cancer Promote multidisciplinary collaboration to address disease-specific questions Determine interest in and commitment to a trial and the potential to accrue Ensure adequate internal review of scientific quality and feasibility of clinical trials, and oversees prioritization of protocols Review clinical research portfolio and develops and brings forward new trials, including investigator-initiated trials Catalyze new multi-investigator, multidisciplinary preclinical and clinical translational research Submit a Protocol for Review All cancer-related hypothesis-driven clinical research studies must undergo a feasibility review by the corresponding DOT or Tumor Board. To submit a study for review, download and complete the application. Download Application Disease-Oriented Teams and Leadership Roster DOT Leader Breast Oncology Ritesh Parajuli, MD Devon Lawson, PhD Erin Lin, DO Gastrointestinal Oncology Oliver Eng, MD Genitourinary Oncology Edward Uchio, MD Michael McClelland, PhD Nataliya Mar, MD Gynecologic Oncology Jill Tseng, MD Lydia Su, PhD Hematologic Malignancies Deepa Jeyakumar, MD Neuro-Oncology Xiao-Tang Kong, MD, PhD Ahmed Mohyeldin, MD, PhD Skin Cancer Kenneth Linden, MD, PhD Bogi Andersen, MD Hepatobiliary-Pancreas David Imagawa, MD, PhD Jennifer Valerin, MD, PhD Nadine Abi-Jaoudeh, MD Murray Korc, MD Tumor Boards At UCI, our tumor boards are a group of doctors and other health care providers with different specialties that meet regularly to discuss cancer cases and share knowledge. The board’s goal is to determine the best possible cancer treatment and care plan for an individual patient. Tumor Board Frequency Contact Neuro Oncology Weekly Naudia Chappell, firstname.lastname@example.org Breast UCIMC/Pacific Breast Weekly Naudia Chappell, email@example.com Gastrointestinal Weekly Naudia Chappell, firstname.lastname@example.org Genitourinary Bi-weekly Naudia Chappell, email@example.com Gynecologic Oncology Weekly Leticia Vazquez, firstname.lastname@example.org Head & Neck Weekly Patrick Pazon, email@example.com Hepatobiliary-Pancreas Weekly William To, firstname.lastname@example.org Lung Bi-weekly Naudia Chappell, email@example.com Malignant Hematology Bi-weekly Naudia Chappell, firstname.lastname@example.org Pigmented Lesion Monthly Naudia Chappell, email@example.com Sarcoma Bi-weekly Naudia Chappell, firstname.lastname@example.org Join a DOT Please contact us at CancerCenter_Committees1@hs.uci.edu to learn more.